A Phase 2, Randomized, Double-Blind, Crossover Study to Examine the Pharmacodynamics, Safety and Tolerability, and Pharmacokinetics of Single Doses of TD-4208 in Subjects Diagnosed With Chronic Obstructive Pulmonary Disease

Trial Profile

A Phase 2, Randomized, Double-Blind, Crossover Study to Examine the Pharmacodynamics, Safety and Tolerability, and Pharmacokinetics of Single Doses of TD-4208 in Subjects Diagnosed With Chronic Obstructive Pulmonary Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Apr 2017

At a glance

  • Drugs Revefenacin (Primary) ; Ipratropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacodynamics
  • Most Recent Events

    • 22 May 2013 Pharmacokinetic results presented at the 109th International Conference of the American Thoracic Society.
    • 05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.
    • 14 Nov 2011 The full results of this study will be presented at an upcoming medical conference, according to a Theravance media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top